ViewRay, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VRAYQ research report →
Price Chart
About the company
ViewRay Systems, Inc. designs, manufactures, and markets magnetic resonance imaging radiation therapy system in the United States and internationally. The company offers MRIdian A3i, an MRI-guided radiation therapy system that provides real-time 3D tissue tracking and automated beam control.
- CEO
- Paul Ziegler
- IPO
- 2015
- Employees
- 295
- HQ
- Oakwood Village, OH, US
Get TickerSpark's AI analysis on VRAYQ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $18.34K
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.51
- Div Yield
- 0.00%
- Gross Margin
- 9.83%
- Op Margin
- -104.81%
- Net Margin
- -105.01%
- ROE
- -85.17%
- ROIC
- -59.34%
Latest fiscal year · YoY change
- Revenue
- $102.21M+45.8%
- Gross Profit
- $10.04M+2898.5%
- Op Income
- $-107,127,000
- Net Income
- $-107,330,000+2.5%
- EPS
- $-0.59+11.9%
- OCF Growth
- -47.7%
- FCF Growth
- -50.2%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 7.07
- RSI (14)
- 47
- Avg Volume
- 4.68K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
ViewRay suspended full-year guidance as it deepens cost cuts and focuses on a strategic review amid delayed revenue conversion and customer caution.· May 10, 2023
- Company is in a strategic alternatives process with Goldman and said it will not disclose specifics until the Board approves a transaction or action.
- Management suspended full-year guidance because customers may delay installations while waiting for clarity from the strategic review.
- Cost-saving actions are expected to reduce expenses by $19 million to $23 million, with about 65% of the savings expected in the current fiscal year.
- ViewRay said it ended Q1 with about $85 million to $86 million in cash and believes it has enough runway to get through the strategic process.
- No backlog orders have been canceled, but some customers are pausing decisions or installations amid the uncertainty.
ViewRay did not give a full quarterly financial table on this call, but management said it ended Q1 with somewhere between $85 million and $86 million in cash. The company announced reductions of $19 million to $23 million in operating expenses, with roughly 65% of those savings expected in the current fiscal year; management also said the full-year run-rate impact is based on the level of spending entering the year. No revenue, EPS, or gross margin figures were stated on the call, and the company suspended guidance for the rest of the year. Management said no customer orders had been canceled, but some installations may be delayed while customers wait for more clarity.
Scott Drake framed the quarter around the strategic review, cash preservation, and guidance suspension. He said the company is working with Goldman on potential outcomes ranging from a sale to recapitalization, and emphasized that the board is trying to choose the path that is best for shareholders. His tone was urgent but controlled: he repeatedly said the process is 100% of management’s focus, that time is not on their side, and that the company is being transparent while trying to preserve flexibility.
Jake Signoriello, in his interim CFO role, focused on the expense cuts and their timing. He clarified that the $19 million to $23 million reduction is an operating expense run-rate cut, not a working-capital measure, and that about 65% of the savings should be realized in the current fiscal year. Management said the cuts are concentrated in G&A, travel, and some commercial expense, while preserving R&D, clinical programs, and customer service. On collections, management said bad debt has historically been minimal and they believe receivables remain collectible.
Analysts pressed management on cash runway, the canceled CFO transition, credit availability, customer behavior, and why guidance was first reduced and then fully withdrawn. Scott Drake declined to discuss the SVB credit line and would only say the company has enough runway to get through the strategic process. He said customers are reacting differently: some are pausing to see how the review ends, while others are still moving ahead, including one customer reportedly considering a second system. Management also said there have been no backlog cancellations and that the company has worked on financing support and backlog monetization, but with only modest success so far.
The bull case from this call is that ViewRay still has a backlog, no canceled orders, and management says customers continue to value MRIdian despite the macro and company-specific uncertainty. The company also highlighted a large clinical footprint, said the team remains focused on patient impact, and pointed to a cost-down project intended to reduce cost of goods by about $1 million and improve installation economics by early 2026.
The main bear case is that revenue conversion is being delayed by distributor payment timing, higher construction costs, and customers waiting for strategic clarity. Management openly said some customers are pausing decisions, working capital needs remain elevated, and the company had to suspend guidance because it cannot predict the timing of installations or the outcome of the strategic review. The company also acknowledged that cash preservation is critical and that it has only had modest success easing financing and working-capital pressures so far.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 95.4%
- Shares Outstanding
- 183.40M
- Float Shares
- 174.95M
of shares held by institutions
9 13F filers
Our VRAYQ coverage
Recent articles, reports, and earnings notes.
No research on VRAYQ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VRAYQ report →